Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments
Combination regimens for SARS-CoV-2 did not affect the time to restart haematological therapy, whereas the occurrence of pneumonia was associated with delayed resumption of chemotherapy. The real benefit of COVID-19 combination therapy in the setting of haematologic malignancies, particularly for early treatment strategies, should be referred to the evidence from randomized controlled trials.
Authors
- Carmela Pinnetti
- Emanuele Rando (ORCID: https://orcid.org/0000-0001-6573-9584)
- Rosaria Santangelo (ORCID: https://orcid.org/0000-0002-8056-218X)
- Andrea Antinori (ORCID: https://orcid.org/0000-0003-2121-4684)
- Antonella Cingolani (ORCID: https://orcid.org/0000-0002-3793-2755)
- Elena Matteini (ORCID: https://orcid.org/0009-0004-2458-1206)
- Valentina Mazzotta (ORCID: https://orcid.org/0000-0002-0240-7504)
- Ilaria Mastrorosa (ORCID: https://orcid.org/0000-0003-1944-662X)
- Simona Sica (ORCID: https://orcid.org/0000-0003-2426-3465)
- Carlo Torti
- Maurizio Sanguinetti (ORCID: https://orcid.org/0000-0002-9780-7059)
- Elisabetta Metafuni (ORCID: https://orcid.org/0000-0002-4780-1273)
- Eleonora Alma (ORCID: https://orcid.org/0000-0001-7008-3313)
- Federico Frondizi (ORCID: https://orcid.org/0000-0002-5295-6341)
- S. Marchetti
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Hospital Universitario Virgen Macarena (ES)
- Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT)
- Centro de Investigación Biomédica en Red (ES)
- Instituto de Biomedicina de Sevilla (ES)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1093/jac/dkaf342
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute